Juan Calle

Juan Calle

Auto-generated profile, based on publicly available information

Juan Calle

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
CSCharles D. Scales
Charles D. Scales
ADAlana C. Desai
Alana C. Desai
JHJonathan D. Harper
Jonathan D. Harper
HLH. Henry Lai
H. Henry Lai
NMNaim M. Maalouf
Naim M. Maalouf
OTOmar Thompson
Omar Thompson
Although maintaining high fluid intake is an effective low-risk intervention for the secondary prevention of urinary stone disease, many patients with stones do not increase their fluid intake. We describe the rationale and design of the Prevention of Urinary Stones With Hydration (PUSH) Study, a randomized trial of a multicomponent behavioral intervention program to increase and maintain high fluid intake. Participants are randomly assigned (1:1 ratio) to the intervention or control arm. The target sample size is 1,642 participants. Adults and adolescents 12 years and older with a symptomatic stone history and low urine volume are eligible. Exclusion criteria include infectious or monogenic causes of urinary stone disease and comorbid conditions precluding increased fluid intake. All participants receive usual care and a smart water bottle with smartphone application. Participants in the intervention arm receive a fluid intake prescription and an adaptive program of behavioral interventions, including financial incentives, structured problem solving, and other automated adherence interventions. Control arm participants receive guideline-based fluid instructions. The primary end point is recurrence of a symptomatic stone during 24 months of follow-up. Secondary end points include changes in radiographic stone burden, 24-hour urine output, and urinary symptoms. Periodic 24-hour urine volumes may not fully reflect daily behavior. With its highly novel features, the PUSH Study will address an important health care problem. National Institute of Diabetes and Digestive and Kidney Diseases. Registered at ClinicalTrials.gov with study number NCT03244189.

1 June 2016 in Cleveland Clinic Journal of Medicine
Verified
Journal Article
Open access
SSSilvi Shah
Silvi Shah
JCJuan Camilo Calle
Juan Camilo Calle
Dietary approaches and medical treatment can prevent recurrence of urinary stones. Some interventions are appropriate for all types of stones, but there are particular risk factors that may need directed therapy.

22 November 2021 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
JFJuan Fulla
Juan Fulla
PPPhornphen Prasanchaimontri
Phornphen Prasanchaimontri
HWHenry C. Wright
Henry C. Wright
MEMarlie Elia
Marlie Elia
SDSmita De
Smita De
JCJuan Calle
Juan Calle

1 October 2017 in Urology
Verified
Journal Article
Closed access
BHBryan D. Hinck
Bryan D. Hinck
VGVishnuvardhan Ganesan
Vishnuvardhan Ganesan
STSarah Tarplin
Sarah Tarplin
JAJohn Asplin
John Asplin
IGIgnacio Granja
Ignacio Granja
MMManoj Monga
Manoj Monga

17 October 2019 in Advances in Urology
Verified
Journal Article
Open access
PDF file
DFDonald Fedrigon
Donald Fedrigon
KAKareem Alazem
Kareem Alazem
SSSri Sivalingam
Sri Sivalingam
MMManoj Monga
Manoj Monga
JCJuan Calle
Juan Calle
Introduction. Both elevated testosterone and polycystic ovary syndrome (PCOS) have been speculated as possible risk factors for kidney stone formation; however, the details of this potential relationship with regards to 24-hour urine metabolic panels and stone composition have not previously been characterized. Methods. A total of 74 PCOS patients were retrospectively identified and matched with a cohort of female stone formers at a 3 : 1 ratio (by age and BMI). All patients had 24-hour urinary metabolic panels and stone compositions. These groups were compared using Pearson chi-square and Student t-tests. Additionally, the PCOS group was differentiated based on free testosterone using multivariate analysis. Results. The case-control cohort showed that PCOS patients had significantly lower sodium excretion p=0.015 and hypernatriuria rates (28.9% vs 50.9%, p=0.009). The PCOS-testosterone cohort demonstrated that high testosterone patients had significantly higher citrate values p=0.041 and significantly lower odds of hypocitraturia (36.7% vs 54.2%, OR = 0.2, p=0.042). The high testosterone group also had higher sodium excretion p=0.058 with significantly higher odds of having hypernatriuria (40.0% vs 13.6%, OR = 13.3, p=0.021). No significant patterns were revealed based on stone composition analysis. Conclusions. Compared to healthy stone formers, PCOS patients did not demonstrate significant differences in 24-hour urine and stone composition values. Elevated free testosterone in PCOS patients has a significant association with higher urinary citrate and sodium values: findings that in and of themselves do not confirm the hypothesized increased risk of stone formation. This patient cohort may provide deeper insight into the interplay between androgens and stone formation; however, further study is needed to fully characterize the possible relationship between PCOS and stone formation.

21 June 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CLCraig B. Langman
Craig B. Langman
DADean Assimos
Dean Assimos
MBMelanie Blank
Melanie Blank
JCJuan Calle
Juan Calle
AGAndreas Grauer
Andreas Grauer
OWon behalf of the Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup)
on behalf of the Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup)
Enteric hyperoxaluria is a medical condition characterized by elevated urinary oxalate excretion due to increased gastrointestinal oxalate absorption. Causative features include fat malabsorption and/or increased intestinal permeability to oxalate. Enteric hyperoxaluria has long been known to cause nephrolithiasis and nephrocalcinosis, and, more recently, an association with CKD and kidney failure has been shown. Currently, there are no US Food and Drug Administration–approved therapies for enteric hyperoxaluria, and it is unclear what end points should be used to evaluate the efficacy of new drugs and biologics for this condition. This study represents work of a multidisciplinary group convened by the Kidney Health Initiative to review the evidence supporting potential end points for clinical trials in enteric hyperoxaluria. A potential clinical outcome is symptomatic kidney stone events. Potential surrogate end points include (1) an irreversible loss of kidney function as a surrogate for progression to kidney failure, (2) asymptomatic kidney stone growth/new stone formation observed on imaging as a surrogate for symptomatic kidney stone events, (3) urinary oxalate and urinary calcium oxalate supersaturation as surrogates for the development of symptomatic kidney stone events, and (4) plasma oxalate as a surrogate for the development of the clinical manifestations of systemic oxalosis. Unfortunately, because of gaps in the data, this Kidney Health Initiative workgroup was unable to provide definitive recommendations. Work is underway to obtain robust information that can be used to inform trial design and medical product development in this space.